Bio-Rad Laboratories, Inc. revenue by segment BIO

Annual Quarterly

Bio-Rad Laboratories, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Clinical Diagnostics at $401.8 million, 61% of the total. By sales mix, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Clinical Diagnostics at $401.8 million, 61% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	2,593	656	651	592	693	653	652	585	668
Operating segments
Clinical Diagnostics	1,590 +3.9% share 61.3%	402 +2.7% share 61.2%	399 +2.6% share 61.3%	364 +1.9% share 61.4%	425 +8.4% share 61.4%	391 share 59.9%	389 share 59.7%	357 share 60.9%	392 share 58.8%
Life Science	1,003 -2.5% share 38.7%	255 -2.8% share 38.8%	252 -4.1% share 38.7%	228 -0.0% share 38.6%	268 -2.6% share 38.6%	262 share 40.1%	263 share 40.3%	229 share 39.1%	275 share 41.2%
Sales mix
Clinical Diagnostics	1,590 +3.9% share 61.3%	402 +2.7% share 61.2%	399 +2.6% share 61.3%	364 +1.9% share 61.4%	425 +8.4% share 61.4%	391 share 59.9%	389 share 59.7%	357 share 60.9%	392 share 58.8%
Life Science	1,003 -2.5% share 38.7%	255 -2.8% share 38.8%	252 -4.1% share 38.7%	228 -0.0% share 38.6%	268 -2.6% share 38.6%	262 share 40.1%	263 share 40.3%	229 share 39.1%	275 share 41.2%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Laboratory Analytical Instruments (SIC 3826)
Listed as: BIO (NYSE), BIO-B (NYSE)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Hercules, CA
SEC filer status: Large accelerated filer
SEC CIK: 12208
Former names: BIO RAD LABORATORIES INC (until Jun 18, 2018)

Other Laboratory Analytical Instruments companies

All 25 Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.